10 June 2021 - The Alzheimer Society of Canada welcomed the new treatment urging Canadian health authorities to complete its required reviews swiftly, so that the drug can be made available as quickly as possible to people living with dementia in the country.
Drug manufacturers Biogen and Japan’s Eisai told Global News that an application for aducanumab was submitted and accepted for review by Health Canada earlier this month.